Neuropsychiatry
When Depression and Anxiety Resist SSRIs — ELNAFAX 37.5 Brings the Dual Power of Serotonin and Norepinephrine Together
Not all depression responds to serotonin alone. Not all anxiety is purely serotonergic in origin. Venlafaxine — a Serotonin and Norepinephrine Reuptake Inhibitor — works on two neurotransmitter pathways simultaneously, providing a clinical depth that SSRIs cannot match in patients who need more than one mechanism addressed. ELNAFAX 37.5 from Quinek Life Sciences starts that treatment at the right dose — the one that builds tolerability before building to full effect.
Why Venlafaxine — and Why 37.5mg Matters
Most psychiatric prescribers in India reach for an SSRI first — and rightly so. SSRIs are effective, well-tolerated and the established first line for depression and anxiety across most presentations. But a meaningful proportion of patients do not respond adequately to SSRIs, or have a clinical picture that specifically benefits from a dual-mechanism approach. This is where Venlafaxine — an SNRI — occupies a distinct and important place in the psychiatric formulary.
Venlafaxine increases both serotonin and norepinephrine at the synapse by blocking their reuptake transporters. This dual action addresses the full neurobiological picture of depression and anxiety — mood, motivation, energy, concentration and the physical symptoms of anxiety — in a way that serotonin-only agents cannot. For patients whose depression includes significant fatigue, concentration difficulties, low energy and physical pain alongside the emotional symptoms, the norepinephrine component of Venlafaxine makes a real clinical difference.
The 37.5mg starting dose of ELNAFAX 37.5 is clinically important for two reasons. First, for panic disorder — where treatment guidelines specifically recommend starting at 37.5mg for 4–7 days before escalating — the 37.5mg tablet provides a prescribable unit that matches the protocol exactly. Second, for elderly patients, those with renal or hepatic impairment, and any patient who may be sensitive to the initial activating effects of an SNRI, 37.5mg gives the prescriber a clean, low-dose starting point without the need to split higher-strength tablets.
“Venlafaxine is dose-dependent in its mechanism. At 37.5–75mg, it is primarily serotonergic. As the dose increases toward 150–225mg, meaningful norepinephrine reuptake inhibition adds a second therapeutic dimension — particularly relevant in severe depression, treatment-resistant cases and conditions where noradrenergic action provides additional benefit.”
— NCBI StatPearls — Venlafaxine
How Venlafaxine Works — The SNRI Mechanism
Venlafaxine Hydrochloride is a phenylethylamine-derivative SNRI. Its primary action is to block two presynaptic reuptake transporters — the Serotonin Reuptake Transporter (SERT) and the Norepinephrine Reuptake Transporter (NET). By preventing the reabsorption of serotonin and norepinephrine back into the presynaptic neuron, Venlafaxine increases the concentration of both neurotransmitters in the synapse — enhancing their activity at postsynaptic receptors.
Serotonin Pathway
Serotonin regulates mood, sleep, appetite, social behaviour and emotional responses. Increasing synaptic serotonin through SERT blockade produces antidepressant, anxiolytic and anti-obsessional effects. This is the primary mechanism at lower doses of Venlafaxine — where the SERT affinity dominates. The serotonergic component of ELNAFAX 37.5 addresses core depressive and anxiety symptoms from the first week of treatment.
Norepinephrine Pathway
Norepinephrine governs alertness, energy, attention, motivation and the body’s stress response. Increasing synaptic norepinephrine through NET blockade improves fatigue, concentration, motivation and physical energy — symptoms that serotonin-only agents often fail to address. Norepinephrine activity becomes more prominent as the dose of Venlafaxine increases — which is why higher doses are often prescribed in severe depression and treatment-resistant cases.
What Conditions ELNAFAX 37.5 Treats
01
Major Depressive Disorder (MDD)
The primary indication. Venlafaxine is indicated for major depressive disorder in adults — both the acute episode and maintenance treatment to prevent relapse. It is particularly appropriate for patients with depression that includes significant fatigue, low motivation, concentration difficulties and physical symptoms of pain — where the noradrenergic component provides a distinct clinical benefit over purely serotonergic agents. ELNAFAX 37.5 is typically used as the starting dose for the first 4–7 days, before stepping up to 75mg once daily as the maintenance dose.
02
Generalised Anxiety Disorder (GAD)
Venlafaxine is indicated for Generalised Anxiety Disorder — persistent, excessive and difficult-to-control worry that causes significant functional impairment. The recommended starting dose for GAD is 37.5–75mg once daily, with a target maintenance dose of 75mg and a maximum of 225mg/day. ELNAFAX 37.5 allows prescribers to start at the lower end of this range, reducing early side effects including nausea, dizziness and heightened anxiety during initiation — which are most common in the first 1–2 weeks.
03
Panic Disorder
Venlafaxine is FDA-approved for panic disorder with or without agoraphobia. Treatment guidelines specifically recommend starting at 37.5mg once daily for 7 days before increasing to 75mg — making ELNAFAX 37.5 the precisely indicated starting formulation for this indication. Patients with panic disorder are often highly sensitive to the initial activating effects of SNRIs and may experience a transient increase in anxiety at the start of treatment. Beginning with 37.5mg minimises this risk and improves the likelihood of successful treatment continuation.
04
Social Anxiety Disorder (SAD)
Venlafaxine extended-release is indicated for social anxiety disorder (social phobia) in adults. The recommended dose is 75mg once daily. ELNAFAX 37.5 serves as the sensitisation starting dose for those patients with social anxiety who are more anxious about starting medication than they are about their social fears — a not uncommon presentation — allowing the prescriber to demonstrate tolerability before reaching the therapeutic dose.
Dosing ELNAFAX 37.5 — Starting Protocol by Indication
Dose increases should be made at intervals of no less than 4 days. Take ELNAFAX 37.5 once daily with food, at approximately the same time each day. Do not crush, chew or split tablets.
Side Effects and Key Clinical Warnings
Blood Pressure Monitoring
Venlafaxine produces dose-related increases in blood pressure. Pre-existing hypertension must be controlled before starting. Blood pressure should be measured at baseline and monitored regularly throughout treatment — particularly at higher doses above 150mg/day.
Discontinuation Syndrome
Like all SNRIs and SSRIs, Venlafaxine must never be stopped abruptly. Discontinuation causes dizziness, nausea, sensory disturbances (“brain zaps”), anxiety and flu-like symptoms. Taper gradually over a minimum of 4 weeks — more slowly from higher doses and in patients on long-term treatment.
MAOI Contraindication
ELNAFAX 37.5 must not be used concurrently with MAOIs or within 14 days of stopping an MAOI. The combination can cause serotonin syndrome — a potentially life-threatening condition characterised by agitation, rapid heart rate, hyperthermia and muscle rigidity.
Common Early Side Effects
Nausea, dry mouth, dizziness, sweating and insomnia are the most commonly reported early side effects — all more pronounced at higher peak concentrations. Taking ELNAFAX 37.5 with food and at the same time each day reduces these. Most patients experience significant improvement in these effects within the first 2 weeks.
What Every Patient Starting ELNAFAX 37.5 Should Be Told
It will not work immediately. Full therapeutic benefit from Venlafaxine takes 2–4 weeks to develop. Some patients feel more anxious or experience increased agitation in the first week — this is normal and transient. The 37.5mg starting dose is specifically designed to minimise this initial period of discomfort.
Take it with food at the same time each day. This reduces nausea and maintains steady drug levels. Take it in the morning if insomnia is a concern, or in the evening if drowsiness is the predominant early effect.
Do not stop without medical guidance. Even missing a few doses can cause discontinuation effects. If treatment is to be ended, it must be tapered slowly under the guidance of the prescribing psychiatrist.
Report any thoughts of self-harm immediately. Like all antidepressants, Venlafaxine carries a warning about the risk of increased suicidal ideation in the early weeks of treatment, particularly in younger patients. Family members and caregivers should be advised to monitor for mood changes, agitation or unusual behaviour and report them promptly.
Quinek Life Sciences — Neuropsychiatry Segment
ELNAFAX 37.5 — Venlafaxine Hydrochloride 37.5mg, Manufactured to WHO-GMP Standards
ELNAFAX 37.5 is Quinek Life Sciences’ Venlafaxine Hydrochloride 37.5mg tablet — providing psychiatrists, neurologists and general physicians with the precise starting-dose unit that Venlafaxine initiation requires. Manufactured at our WHO-GMP, GLP and ISO certified facilities, ELNAFAX 37.5 delivers consistent potency and reliable bioavailability in every tablet.
Our neuropsychiatry range addresses the full spectrum of mood and anxiety conditions managed across India’s growing psychiatric practice — and ELNAFAX 37.5 is the formulation that starts that treatment on the right footing. If you are a psychiatrist, neurologist or distributor serving the neuropsychiatry space in India, we would like to speak with you.
Starting at 37.5mg Is Not Playing It Safe — It Is Doing It Right
The 37.5mg dose is not a compromise. It is the clinically appropriate starting point for a medicine whose therapeutic value increases with dose — and whose tolerability must be established at initiation before that dose can be built. For panic disorder, it is the guideline-recommended start. For sensitive patients and the elderly, it is the standard of care. And for any prescriber who wants to give Venlafaxine the best chance of being taken consistently — and therefore working — it is where ELNAFAX 37.5 begins.
ELNAFAX 37.5 from Quinek Life Sciences — Venlafaxine Hydrochloride 37.5mg — the right dose, to start the right treatment, in the right patient.
Medical Disclaimer: This article is for educational purposes and healthcare professional reference only. Venlafaxine must be prescribed and monitored by a qualified psychiatrist or licensed physician. Never start, change or stop psychiatric medication without medical supervision. If you are in mental health crisis, contact iCall (9152987821) or Vandrevala Foundation (1860-2662-345).
Sources: NCBI StatPearls — Venlafaxine · Drugs.com Prescribing Information · Mayo Clinic — Venlafaxine · NAMI Medication Guide · iMedic Clinical Reference 2026 · Quinek Life Sciences Neuropsychiatry Segment
